摘要
Atherosclerosis, stable myocardial infarction (MI), non-stable MI are the most common manifestations of coronary artery disease (CAD). CAD is one of leading causes of substantial morbidity and mortality in the global scenario. There are several biomarkers and methods for the diagnosis of CAD such as cardiac specific troponin, electrocardiogram (ECG), CT angiography. Recently, many studies have shown that miRNAs are involved in regulation of gene expression on post-transcriptional level by inhibiting translation protein from mRNA that miRNAs dysregulated in the plasma of patients with CAD (cases). These suggested miRNAs can be detected in circulating blood which might be a diagnostic and prognostic biomarker for CAD. Besides these studies, there is an additional need in studies about miRNAs family, so that miRNAs might serve as potential therapeutic target in the treatment of CAD, as well as other complex diseases. In this review, we have summarized some studies as miRNAs as diagnostic and assessment of prognosis biomarker in patients with CAD.
Atherosclerosis, stable myocardial infarction (MI), non-stable MI are the most common manifestations of coronary artery disease (CAD). CAD is one of leading causes of substantial morbidity and mortality in the global scenario. There are several biomarkers and methods for the diagnosis of CAD such as cardiac specific troponin, electrocardiogram (ECG), CT angiography. Recently, many studies have shown that miRNAs are involved in regulation of gene expression on post-transcriptional level by inhibiting translation protein from mRNA that miRNAs dysregulated in the plasma of patients with CAD (cases). These suggested miRNAs can be detected in circulating blood which might be a diagnostic and prognostic biomarker for CAD. Besides these studies, there is an additional need in studies about miRNAs family, so that miRNAs might serve as potential therapeutic target in the treatment of CAD, as well as other complex diseases. In this review, we have summarized some studies as miRNAs as diagnostic and assessment of prognosis biomarker in patients with CAD.
